


## AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A phenoxypropylamine compound of the formula (I)



wherein each symbol in the formula means as follows:


a bond represented by a solid line and a dotted line shows a double bond or a single bond;

X is a hydrogen atom, a hydroxy group, a C<sub>1</sub>-C<sub>8</sub> alkoxy group, an acyloxy group or an oxo group;

provided that when R<sup>1</sup> is a group of the following formula (2),

X should not be a hydrogen atom;

R<sup>1</sup> is a group of the following formula



wherein

Y is O or S;

Ar is optionally substituted aromatic hydrocarbon;

R<sup>2</sup> is optionally substituted aryl group or optionally substituted aromatic heterocyclic group;


R<sup>5</sup> is optionally substituted aryl group or optionally substituted aromatic heterocyclic group;

- Z is void or  $-\text{CH}_2-$ , and
- $\text{R}^6$  is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or  $\text{C}_1\text{-C}_8$  alkoxy group;
- $\text{R}^3$  is a hydrogen atom, a  $\text{C}_1\text{-C}_{18}$  alkyl group or a halogen atom;
- V is  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{S}-$  or the formula  $-\text{N}(\text{R}^*)-$  wherein  $\text{R}^*$  is hydrogen atom,  $\text{C}_1\text{-C}_{18}$  alkyl group or optionally substituted aralkyl group;
- W is void or  $-\text{CH}_2-$  or  $-\text{C}(=\text{O})-$ ;
- $\text{R}^7$  is a  $\text{C}_1\text{-C}_4$  hydroxyalkyl group, an acyl group, an optionally substituted saturated or unsaturated heterocyclic group, an optionally substituted fused heterocyclic group, a  $\text{C}_1\text{-C}_4$  alkylsulfonyl group or the formula  $-\text{Q-R}^9$


wherein

Q is  $-\text{C}(=\text{O})-$ ,  $-\text{C}(=\text{S})-$ ,  $-\text{CH}_2-$  or  $-\text{S}(=\text{O})_2-$ , and


$\text{R}^9$  is a group of the following formula




(5)




(6)



(7)




(8)




(9)




(10)



(11)



(12)




(13)

or -NH-NH-R<sup>15</sup>

wherein R<sup>10</sup> and R<sup>11</sup> are each independently hydrogen atom, C<sub>1</sub>-C<sub>18</sub> alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, R<sup>12</sup> is hydrogen atom, optionally substituted aryl group, C<sub>1</sub>-C<sub>18</sub> alkyl group, C<sub>1</sub>-C<sub>8</sub> alkoxy group or acyl group, and R<sup>15</sup> is hydrogen atom, phenyl group, C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>2</sub> halogenated alkyl group, halogen atom, C<sub>2</sub>-C<sub>4</sub> alkenyl group, C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group;

~~provided that when R<sup>7</sup> is a group of the above formula (2), R<sup>7</sup> should not be C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl group or acyl group, and R<sup>10</sup> and R<sup>11</sup> are not each hydrogen atom at the same time; or~~

~~R<sup>7</sup> and W in combination may form a ring of the following formula-~~



wherein-

~~E — is oxygen atom or sulfur atom, and~~


~~Q' — is an optionally substituted 4 to 7-membered heterocycle having 1 or 2 hetero atom(s) selected from the group consisting of nitrogen atom and oxygen atom in the ring, in which case V is hydrogen atom; and~~

~~R<sub>a</sub>, R<sub>b</sub> and R<sub>c</sub> are each independently a hydrogen atom, a C<sub>1</sub>-C<sub>18</sub> alkyl group, a hydroxy group, a C<sub>1</sub>-C<sub>8</sub> alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;~~

~~provided that when R<sup>7</sup> and W are bonded to form a ring of the above formula (14), R<sub>a</sub>, R<sub>b</sub> and R<sub>c</sub> are not each hydroxy group or C<sub>1</sub>-C<sub>8</sub> alkoxy group;~~

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. (Currently Amended) The compound of the claim 1, which is represented by the formula (I)




wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

X is a hydrogen atom, a hydroxy group, a C<sub>1</sub>-C<sub>8</sub> alkoxy group, an acyloxy group or an oxo group;

R<sup>1</sup> is a group of the following formula



wherein

~~Y~~ is O or S,

~~Ar~~ is optionally substituted benzene or naphthalene,

~~R<sup>2</sup>~~ is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

R<sup>5</sup> is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or -CH<sub>2</sub>-, and

R<sup>6</sup> is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxy carbonyl group, cyano group or C<sub>1</sub>-C<sub>8</sub> alkoxy group;

R<sup>3</sup> is a hydrogen atom, a C<sub>1</sub>-C<sub>18</sub> alkyl group or a halogen atom;

~~V~~ is ~~-CH<sub>2</sub>-, -O-, -S- or the formula -N(R<sup>\*</sup>)- wherein R<sup>\*</sup> is hydrogen atom, C<sub>1</sub>-C<sub>18</sub> alkyl group or optionally substituted aralkyl group;~~


W is void or -CH<sub>2</sub>- or -C(=O)-;

R<sup>7</sup> is a C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl group, an acyl group, an optionally substituted saturated or unsaturated heterocyclic group, an optionally substituted fused heterocyclic group, a C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl group or the formula -Q-R<sup>9</sup>


wherein

Q is -C(=O)-, -C(=S)-, -CH<sub>2</sub>- or -S(=O)<sub>2</sub>-, and


R<sup>9</sup> is a group of the following formula




(5)




(6)




(7)






(8)



(9)



(10)



or -NH-NH-R<sup>15</sup>

wherein R<sup>10</sup> and R<sup>11</sup> are each independently hydrogen atom, C<sub>1</sub>-C<sub>18</sub> alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, R<sup>12</sup> is hydrogen atom, optionally substituted aryl group, C<sub>1</sub>-C<sub>18</sub> alkyl group, C<sub>1</sub>-C<sub>8</sub> alkoxy group or acyl group, and R<sup>15</sup> is hydrogen atom, phenyl group, C<sub>1</sub>-C<sub>4</sub> alkyl group, C<sub>1</sub>-C<sub>2</sub> halogenated alkyl group, halogen atom, C<sub>2</sub>-C<sub>4</sub> alkenyl group, C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group; and

R<sub>a</sub>, R<sub>b</sub> and R<sub>c</sub> are each independently a hydrogen atom, a C<sub>1</sub>-C<sub>18</sub> alkyl group, a hydroxy group, a

C<sub>1</sub>-C<sub>8</sub> alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group; provided that when R<sup>†</sup> is a group of the above formula (2), R<sup>†</sup> should not be C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl group or acyl group, and R<sup>††</sup> and R<sup>††</sup> are not each hydrogen atom at the same time;


an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

**3. (Currently Amended)** The compound of the claim 2, which is represented by the formula (I) wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

X is a hydroxy group;

$R^1$  is a group of the following formula



wherein

$R^5$  is optionally substituted phenyl group or naphthyl group,

Z is void, and

$R^6$  is hydrogen atom;





$R^3$  is a hydrogen atom or a  $C_1$ - $C_4$  alkyl group;

V is  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{S}-$  or  $-\text{N}(\text{R}^*)-$

wherein  $\text{R}^*$  is hydrogen atom,  $C_1$ - $C_6$  alkyl group or optionally substituted aralkyl group;

W is void;

$R^7$  is a group of the following formula








or the formula  $-\text{CO}-\text{R}^9$


wherein

$R^8$  is hydrogen atom, phenyl group,  $C_1$ - $C_4$  alkyl group,  $C_1$ - $C_2$  halogenated alkyl group, halogen atom,  $C_2$ - $C_4$  alkenyl group,  $C_1$ - $C_4$  hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group, and

$R^9$  is a group of the following formula



or




wherein  $R^{10}$  and  $R^{11}$  are each independently hydrogen atom,  $C_1$ - $C_{18}$  alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, and  $R^{12}$  is hydrogen atom, optionally substituted aryl group,  $C_1$ - $C_{18}$  alkyl group,  $C_1$ - $C_8$  alkoxy group or acyl group; and

$R_a$ ,  $R_b$  and  $R_c$  are each a hydrogen atom;



an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

**4. (Previously Amended)** The compound of claim 2 ~~or claim 6~~, which is represented by the formula (I')



wherein each symbol is as in claim 2,  
an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

**5. (Currently Amended)** The compound of claim 2, which is selected from the group consisting of

- (1) 1-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)furan-2-ylcarbonyl)pyrrolidine,
- (2) 4-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)furan-2-ylcarbonyl)morpholine,
- (4) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)furan-2-carboxamide,
- (12) 1-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)thiophen-2-ylcarbonyl)pyrrolidine,
- (13) 4-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)thiophen-2-ylcarbonyl)morpholine,

(15) 4-(2-hydroxy-3-(4-(naphthalen-1-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)thiophene-2-carboxamide,-

(17) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)thiophene-2-carboxamide,-

(20) 4-(7-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)furan-2-ylcarbonyl)morpholine,

(21) 7-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)furan-2-carboxamide,

(27) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethyl-1H-indole-2-carboxamide,-

(30) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethyl-1-methylindole-2-carboxamide,-

(35) 1-(2-(5-methyl-1,2,4-oxadiazol-3-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(37) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(38) 1-(2-(5-trifluoromethyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(39) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-7-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(42) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-indole-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,-

(44) 1-(2-(3-methyl-1,2,4-oxadiazol-5-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(48) 1-(2-(5-methyloxazol-2-yl)benzo(b)furan-7-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(81) 3-(4-(3,4-dichlorophenyl)piperidino)-1-(2-(5-methyloxazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol,

(88) 1-(4-(3,4-dichlorophenyl)piperidino)-3-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol, and

(93) 3-(4-(3,4-dimethylphenyl)piperidino)-1-(2-(5-ethyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol,


an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

**6-12. (Deleted)**

**13. (Original)** A pharmaceutical composition comprising at least one member selected from the group consisting of a compound of claim 1, an optically active compound thereof, a pharmaceutically acceptable salt thereof and a hydrate thereof, and a pharmaceutically acceptable carrier.

**14-16. (Deleted)**

**17. (Currently Amended)** A compound of the formula (II)




wherein each symbol in the formula means as follows:

X is a hydrogen atom, a hydroxy group, a C<sub>1</sub>-C<sub>8</sub> alkoxy

group or an acyloxy group or an oxo group;

$R^1$  is a group of the following formula



wherein

$Y$  is O or S;

$Ar$  is optionally substituted benzene or naphthalene;

$R^2$  is optionally substituted aryl group or optionally substituted aromatic heterocyclic group;

$R^5$  is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

$Z$  is void or  $-CH_2-$ , and

$R^6$  is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or  $C_1-C_8$  alkoxy group;

provided that when  $V$  is  $-N(R^*)$ ,  $R^6$  should not be hydroxy group;

$R^3$  is a hydrogen atom, a  $C_1-C_{18}$  alkyl group or a halogen atom;

$V$  is  $-CH_2-$ ,  $-O-$ ,  $-S-$  or the formula  $-N(R^*)$ ;

wherein

$R^*$  is hydrogen atom,  $C_1-C_{18}$  alkyl group or optionally substituted aralkyl group;

$W$  is void,  $-CH_2-$  or  $-C(=O)-$ ;


$R^{14}$  is a hydrogen atom or a  $C_1-C_4$  alkyl; and

$Ra$ ,  $Rb$  and  $Rc$  are each independently a hydrogen atom, a  $C_1-C_{18}$  alkyl group, a hydroxy group, a  $C_1-C_8$  alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

**18-20. (Deleted)**

**21. (Currently Amended)** The compound of claim 3, which is represented by the formula (I')



wherein each symbol is as in claim 2 3,

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

**22. (New)** A method of treating depression, which comprises administering, to a mammal, an effective amount of a compound of claim 1, an optically active compound thereof, pharmaceutically acceptable salt thereof or a hydrate thereof.

**23. (New)** 2-(4-hydroxybenzo(b)furan-2-yl)-5-methyl-1,3,4-oxadiazole.

**24. (New)** (S)-2-(4-glycidyoxybenzo(b)furan-2-yl)-5-methyl-1,3,4-oxadiazole.